ClinicalTrials.gg
RecruitingNCT05650632Updated Nov 10, 2026

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

A Phase 1 interventional study of Etentamig (ABBV-383) in Multiple Myeloma, sponsored by AbbVie. Recruiting at 44 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 7 months later.
Updated Nov 10, 2026Enrollment updatedEligibility revised+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
250
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing etentamig in Multiple Myeloma — 6 open to participants now, 10 under way, 3 of them phase 3. etentamig · Multiple Myeloma.

Planned enrollment
5th of 10
250 · median 235
Started
2023
the only one that year
Phase 1
4 of 10
2 open now
Registered
3rd of 10
by date
Lead sponsor
9 of 10
AbbVie

Among the 10 studies testing etentamig in Multiple Myeloma, this one is the 5th largest by planned enrollment, is the only one that started in 2023, is one of 4 in phase 1, and was the 3rd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

6 of the 10 studies testing etentamig in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About etentamig

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing etentamig in Multiple Myeloma, or all of them as a file.
02

Study summary

Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine adverse events and change in disease symptoms of etentamig (ABBV-383) in adult participants with relapsed/refractory (R/R) MM.

Etentamig (ABBV-383) is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study is broken into 4 Arms; Arm A (Parts 1 and 2), Arm B and Arms C \& D. Arm A includes 2 parts: step-up dose optimization (Part 1) and dose expansion (Part 2). In Part 1, different level of step-up doses are tested followed by the target dose of etentamig (ABBV-383). In Part 2, the step-up dose identified in Part 1 (Dose A) will be used followed by the target dose A of etentamig (ABBV-383). In Arm B a flat dose of etentamig (ABBV-383) will be tested. In Arms C \& D, the step-up dose identified in Arm A will be used followed by the target dose of etentamig (ABBV-383) to investigate outpatient administration of etentamig (ABBV-383). In Arm E, etentamig (ABBV-383) will be investigated for outpatient administration. Around 250 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 50 sites across the world.

Participants will receive etentamig (ABBV-383) as an infusion into the vein in 28 day cycles for approximately 3 years.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Multiple Myeloma
  • Cancer
  • ABBV-383
  • B-Cell Maturation Antigen
04

Who can participate

The criteria were revised on the registry on Nov 10, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have as outlined in the protocol.
  • (ECOG) performance of \<= 2. Arm C and Arm D: ECOG performance of \<= 1.
  • (R/R) multiple myeloma (MM) with documented evidence of progression during or after the participant's last treatment regimen based on the investigator's determination of the International Myeloma Working Group (IMWG) 2016 criteria.
  • Must be naïve to treatment with etentamig (ABBV-383).
  • Arm A: Must have received at least 3 or more , including a proteasome inhibitor (PI), an immunomodulatory imide drug (IMiD), and an anti-CD38 monoclonal antibody.
  • Arm B: Must have received at least 2 or more lines of therapy, including exposure to a PI, an IMiD, an anti-CD38 monoclonal antibody, and a prior B-cell maturation antigen (BCMA)-targeted therapy (must be an anti-drug conjugate [ADC] or chimeric antigen receptor T-cell [CAR-T] directed against BCMA).
  • Arm C: Must have received at least 2 or more lines of therapy, including exposure to a PI, an IMiD, and an anti-CD38 monoclonal antibody. Must be suitable for outpatient administration of etentamig (ABBV-383).
  • Arm D: Must have received at least 1 and no more than 3 prior lines of therapy, including exposure to a PI, an IMiD, or an anti-CD38 monoclonal antibody. Must be suitable for outpatient administration of etentamig (ABBV-383).
  • Arm E: Must have received 1 line of therapy, including exposure to a PI, an IMiD, and an anti-CD38 monoclonal antibody. Must have never received BCMA-targeted therapy.

Exclusion criteria

Exclusion Criteria:

  • Arm A: Received BCMA-targeted therapy.
  • Arm C and Arm D: Rapidly progressing disease per investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Arm A (Part 1): ABBV-383 Dose Escalation

    B-cell maturation antigen (BCMA) naïve participants will receive different doses of ABBV-383 in 28 day cycles.

    Drug: Etentamig (ABBV-383)

  • Experimental
    Arm A (Part 2): ABBV-383 Dose Expansion

    BCMA naïve participants will receive the dose of ABBV-383 dose A in 28 day cycles.

    Drug: Etentamig (ABBV-383)

  • Experimental
    Arm B: ABBV-383 BCMA Exposed

    Participants previously exposed to BCMA-targeted agents will receive ABBV-383 Dose A in 28 day cycles.

    Drug: Etentamig (ABBV-383)

  • Experimental
    Arm C: ABBV-383 Step Up

    Participants will receive step up dose and full target dose of ABBV-383 in 28 day cycles.

    Drug: Etentamig (ABBV-383)

  • Experimental
    Arm D: ABBV-383 Step Up

    Participants who have received at least 1 and no more than 3 prior lines of therapy will receive step up dose and full target dose of ABBV-383 in 28 day cycles.

    Drug: Etentamig (ABBV-383)

  • Experimental
    Arm E: ABBV-383 Step Up

    Participants who have received 1 line of therapy will receive step up dose and full target dose of ABBV-383 in 28 day cycles.

    Drug: Etentamig (ABBV-383)

Interventions

06

What researchers measure

Primary outcomes

  1. Arm A (Part 1 and Part 2) Arm C, Arm D, and Arm E: Number of Grade >= 2 Cytokine Release Syndrome (CRS) Events

    CRS is defined by fever, hypoxia, and hypotension and graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) guidelines

    Time frame: Up to Day 28

  2. Arm B: Number of Adverse Events (AEs) of Special Interest (CRS and Immune Effector Cell-associated Neurotoxicity Syndrome [ICANS])

    AEs of special interest will be graded according to American Society for Transplantation and Cellular Therapy (ASTCT) 2019 guidelines. All other AEs will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

    Time frame: Up to Day 28

Secondary outcomes

  1. Arm A, Arm C. Arm D, and Arm E: Number of Cytokine Release Syndrome (CRS) Events

    CRS is defined by fever, hypoxia, and hypotension and graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) guidelines

    Time frame: Up to 3 Years

  2. Arm E-Overall Response Rate (ORR)

    ORR is defined as the percentage of participants with a confirmed partial response (PR), very good partial response (VGPR), complete response (CR) or stringent complete response (sCR) per Investigator review according to International Myeloma Working Group (IMWG) 2016 criteria.

    Time frame: Up to 3 Years

  3. Arm E-Duration of Response (DOR)

    DOR is defined as the time from the date of achieving the first confirmed sCR/CR/VGPR/PR to the date of recurrence, disease progression according to IMWG 2016 criteria, as determined by the investigator, or death of any cause, whichever occurs earlier.

    Time frame: Up to 3 Years

07

Study locations

39 of 44 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Aug 2029, 77 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 77 months is above that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2022
First posted
Dec 14, 2022
StartActual
Mar 21, 2023
Primary completionEst.
Aug 2029
CompletionEst.
Aug 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 6 sites removed
Show 4 added (3 United States, 1 United Kingdom)
  • East Jefferson General Hospital /ID# 251204 · Metairie, United States
  • Icahn School of Medicine at Mount Sinai /ID# 251166 · New York, United States
  • Fred Hutchinson Cancer Center - Seattle - Eastlake Avenue East /ID# 267940 · Seattle, United States
  • UCLH NHS FT - NIHR UCLH Clinical Research Facility /ID# 251357 · London, United Kingdom
Show 6 removed
  • Tulane University School of Medicine /ID# 251204 · New Orleans, United States
  • Maryland Oncology Hematology - Silver Spring /ID# 268562 · Silver Spring, United States
  • Mt Sinai /ID# 251166 · New York, United States
  • Baptist Memorial Hospital /ID# 280677 · Memphis, United States
  • Fred Hutchinson Cancer Center. /ID# 267940 · Seattle, United States
  • University College London Hospital /ID# 251357 · London, United Kingdom
Nov 10, 2026
Enrollment
210→250
Nov 10, 2026
Eligibility
1 inclusion criterion added
What changed in the criteria
Inclusion criteria
  • AddedArm E: Must have received 1 line of therapy, including exposure to a PI, an IMiD, and an anti-CD38 monoclonal antibody. Must have never received BCMA-targeted therapy.
Nov 10, 2026
Interventions
Arms added: Arm E: ABBV-383 Step Up
Nov 10, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedArm A (Part 1 and Part 2) Arm C, Arm D, and Arm DE: Number of Grade >= 2 Cytokine Release Syndrome (CRS) EventsTime frame: Up to Day 28
Nov 10, 2026
Secondary outcomes
1 edited, 2 added
What changed in the outcomes
  • EditedArm A, Arm C. Arm D, and Arm DE: Number of Cytokine Release Syndrome (CRS) EventsTime frame: Up to 3 Years
  • AddedArm E-Overall Response Rate (ORR)Time frame: Up to 3 Years
  • AddedArm E-Duration of Response (DOR)Time frame: Up to 3 Years
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    4 sites added, 6 sites removed
    Show 4 added (3 United States, 1 United Kingdom)
    • East Jefferson General Hospital /ID# 251204 · Metairie, United States
    • Icahn School of Medicine at Mount Sinai /ID# 251166 · New York, United States
    • Fred Hutchinson Cancer Center - Seattle - Eastlake Avenue East /ID# 267940 · Seattle, United States
    • UCLH NHS FT - NIHR UCLH Clinical Research Facility /ID# 251357 · London, United Kingdom
    Show 6 removed
    • Tulane University School of Medicine /ID# 251204 · New Orleans, United States
    • Maryland Oncology Hematology - Silver Spring /ID# 268562 · Silver Spring, United States
    • Mt Sinai /ID# 251166 · New York, United States
    • Baptist Memorial Hospital /ID# 280677 · Memphis, United States
    • Fred Hutchinson Cancer Center. /ID# 267940 · Seattle, United States
    • University College London Hospital /ID# 251357 · London, United Kingdom
    Enrollment 210→250
    Eligibility 1 inclusion criterion added
    What changed in the criteria
    Inclusion criteria
    • AddedArm E: Must have received 1 line of therapy, including exposure to a PI, an IMiD, and an anti-CD38 monoclonal antibody. Must have never received BCMA-targeted therapy.
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedArm A (Part 1 and Part 2) Arm C, Arm D, and Arm DE: Number of Grade >= 2 Cytokine Release Syndrome (CRS) EventsTime frame: Up to Day 28
    Secondary outcomes 1 edited, 2 added
    What changed in the outcomes
    • EditedArm A, Arm C. Arm D, and Arm DE: Number of Cytokine Release Syndrome (CRS) EventsTime frame: Up to 3 Years
    • AddedArm E-Overall Response Rate (ORR)Time frame: Up to 3 Years
    • AddedArm E-Duration of Response (DOR)Time frame: Up to 3 Years
    Interventions Arms added: Arm E: ABBV-383 Step Up
    + 3 other changes: identifiers, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05650632
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Dec 14, 2022
Start date
Mar 21, 2023
Primary completion
Aug 2029 (estimated)
Completion
Aug 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etentamig

Start the discussion